Gadovist®: the only 1.0 M gadolinium based contrast agent (GBCA)1
Gadovist is a macrocyclic, extracellular GBCA2 that can be used to enhance the contrast in MRI of any body region3
Gadovist is used for visualisation and diagnosis of pathological lesions, and for evaluation of perfusion and blood flow2
Gadovist is indicated in adults and children of all ages (including term neonates) for:3
- Contrast enhancement in cranial and spinal MRI
- Contrast enhancement MRI of liver or kidneys in patients with high suspicion or evidence of having focal lesion to classify these lesions as benign or malignant
- Contrast enhancement in MRA
Gadovist can also be used for MRI of pathologies of the whole body; it facilitates visualisation of abnormal structures or lesions, and helps in the differentiation between healthy and pathological tissue3
Gadovist: highly rated contrast enhancement4 in five key specialist areas
- MRA and CNS perfusion imaging
The benefits of Gadovist
Gadovist: high signal intensity5 and excellent contrast enhancement through rating by healthcare professionals4,6
Due to its 1.0 M concentration3 and high relaxivity5, Gadovist has a higher T1-shortening effect per milliliter than other GBCAs5,7
- T1-relaxivity of Gadovist at 1.5 T is higher than that of other available, non-specific extracellular GBCAs (Dotarem and ProHance)5
T1-shortening times of Gadovist and other GBCAs with 1mL/L volume concentration of contrast media.
*From 01 February 2018, the licences for Omniscan and Magnevist IV 0.5mmol have been suspended, and the license for MultiHance has been amended for use in liver imaging only; following the European Medical Agency (EMA) European Commission Article 31 Referral, Gadolinium Presence in the Brain.
Adapted from reference 7
Calculated for blood at 1.5 T using T10 = 1,200 ms
The only 1.0 M GBCA1 indicated for whole body scanning in patients of all ages3
Gadovist has the highest T1-shortening effect per milliliter of all available GBCAs5,7
- Its high signal intensity5 and concentration result in excellent contrast enhancement through rating by healthcare professionals4,6 and highly rated image quality4,6
Gadovist has been administered more than 29 million times in clinical practice8, is well tolerated4,6 and has a well-established safety profile in a wide variety of patient populations4,6
- In a study of more than 23,000 patients, 0.9% reported 251 adverse events (AE). For these AEs, 0.7% were categorized as adverse drug reactions (ADR), with the intensity of the ADRS reported as 83.6% mild, 13.2% moderate and 2.3% severe4
Gadovist is the only 1.0 M GBCA1
- The injection volume is half that of 0.5 M GBCAs, therefore administration takes half the time9
- A range of vials and pre-filled syringes allow flexible dosing and administration
Access to prescribing information can be found at the bottom of the pageLearn More
- Bellin MF. and Van Der Molen AJ. Eur J Radiol 2008;66(2):160-167.
- Scott LJ. Clin Drug Investig 2013;33(4):303-314.
- Gadovist Summary of Product Characteristics. October 2017.
- Prince MR et al. Eur Radiol 2016;10.1007/s00330-016-4268-8.
- Rohrer M et al. Invest Radiol 2005;40(11):715-724.
- Glutig K et al. Pediatr Radiol 2016;46(9):1317-1323.
- Bayer Data on File. T1 Shortening Calculation. January 2018.
- Endrikat J et al. Invest Radiol 2016;51:537-543.
- Reiser M et al. Magnetic Resonance Tomography. Springer-Verlag Berlin Heidelberg; 2008, pp 98-99.